You asked, we listened! Next month, we are launching a new and improved user profile experience to keep you connected.In the meantime, if you would like to update your profile please contact our office at 507-284-2317 or email us at

American Society of Clinical Investigation names new Mayo members Liewei Wang, M.D., Ph.D., and Martin Fernandez-Zapico, M.D.

The American Society of Clinical Investigation has named two new members from Mayo Clinic – Liewei Wang, M.D., Ph.D. (MPET ’03, PHAR ’03), Department of Molecular Pharmacology and Experimental Therapeutics; and Martin Fernandez-Zapico, M.D. (GI ’02), Division of Medical Oncology.

Mayo Clinic now has 39 members in this honorary society of physician-scientists.

Liewei Wang, M.D., Ph.D. – American Society of Clinical Investigation

Dr. Wang is a specialist in pharmacogenomics. In her laboratory, she uses genomic-based tools to identify biomarkers that can help predict a patient response to a given drug or dose. She also researches the genomics of cancer tumors to determine the most effective anti-tumor drugs.

“It is a real honor for me to be elected as a member of this group that includes many outstanding physician-scientists from great academic institutions,” says Dr. Wang. “This is also recognition of Mayo as a premier academic medical center where basic and clinical scientists can perform state-of-the-art translational research and a place that provides a very supportive environment for translational research.”

Dr. Wang completed a postdoctoral fellowship and a doctorate degree at Mayo Clinic Graduate School of Biomedical Sciences. She received her medical degree from Fudan University Medical School in China.

Martin Fernandez-Zapico, M.D. – American Society of Clinical Investigation

Martin Fernandez-Zapico, M.D.

Dr. Fernandez-Zapico’s research aims to understand the epigenetic pathways regulating the initiation and progression of pancreatic cancer. His two main areas of focus are the signaling regular of transcriptional processes that fine-tune the growth of cancer and the epigenetic regulation of the tumor microenvironment. He and his team believe both avenues of research will provide a foundation for new cancer therapies for pancreatic cancer.

“I feel honored, pleased, excited and happy,” says Dr. Fernandez-Zapico. “This affirms my commitment to this disease, my present line of research and the choices I’ve made during my career. It says I’m on the right track with my work and the path I selected is a good one. Now I can proceed with even greater confidence.”

Dr. Fernandez-Zapico completed research fellowships at Mayo Clinic Graduate School of Biomedical Sciences and received his medical degree from the National University of Cordoba in Cordoba, Argentina.





Recommended reading

Posts about similar topics:

Shopping cart0
There are no products in the cart!